POst Stroke Intervention Trial In Fatigue (POSITIF)
Launched by UNIVERSITY OF EDINBURGH · May 29, 2018
Trial Information
Current as of June 10, 2025
Completed
Keywords
ClinConnect Summary
Primary Objective
Does a brief cognitive behavioural intervention for post-stroke fatigue lead to clinically relevant improvements in fatigue after 6 months? Fatigue will be assessed using the self-reported Fatigue Assessment Scale (FAS) which has been validated for use in stroke (14). This scale includes both mental and physical fatigue. Our data shows that a difference of approximately 5 points in FAS was associated with a clinically significant difference in people with stroke (15); the literature on stroke patients suggests that a difference in four points on the scale is considered to...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years
- • Stroke 3 months to 2 years previously. Both ischaemic and haemorrhagic, including subarachnoid haemorrhage
- • Capacity to consent
- • Not living in nursing home.
- • Medically stable,
- • Answers 'Yes' to both the following questions about fatigue
- • 'Do you feel tired all the time or get tired very quickly since your stroke'?
- • Would you like additional help and support for this?
- Exclusion Criteria:
- • Unlikely to be available for follow-up for the next 6 months e.g. no fixed home address
- • Other life-threatening illness (e.g. advanced cancer or advanced heart failure) that will make survival for 6 months unlikely
- • Aphasia or cognitive impairment which is severe enough to prevent participation in the intervention. To assess this, patients will self-report their language and cognition from the relevant domains in the Short Stroke Impact Scale ('In the past week, how difficult was it for you to think quickly?' and 'In the past week, how difficult was it to understand what was being said to you in a conversation?') Those who respond 'very difficult' or 'could not do at all' to either question will be excluded. (24). Those who might be in these categories are likely to be unable to complete the form(s) and thus self-select to decline to return the paperwork.
- • Actively suicidal, requiring in-patient treatment for depression, depression related cognitive impairment. (see below)
- • High anxiety as part of a post-traumatic stress disorder syndrome or panic disorder (see below)
- • Previously enrolled in this trial
- • Enrolled in another talking therapy trial
- • Inability to understand spoken and/or written English
About University Of Edinburgh
The University of Edinburgh, a prestigious institution renowned for its commitment to research excellence and innovation, serves as a leading clinical trial sponsor dedicated to advancing healthcare through rigorous scientific inquiry. With a strong emphasis on multidisciplinary collaboration, the university facilitates cutting-edge clinical studies that aim to explore novel therapies and improve patient outcomes. Leveraging its extensive network of researchers, healthcare professionals, and state-of-the-art facilities, the University of Edinburgh is at the forefront of translating scientific discoveries into practical applications, thereby contributing significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Edinburgh, , United Kingdom
Kirkcaldy, , United Kingdom
Airdrie, , United Kingdom
Patients applied
Trial Officials
Gillian Mead, MB BChir MA MD FRCP
Principal Investigator
University of Edinburgh
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials